Addex Therapeutics (NASDAQ:ADXN) Releases Earnings Results

Addex Therapeutics (NASDAQ:ADXN) issued its quarterly earnings results on Thursday. The company reported ($1.50) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.01 million for the quarter.

Here are the key takeaways from Addex Therapeutics’ conference call:

• Addex said its GABAB positive modulator for chronic cough showed robust antitussive activity in preclinical models, including non-human primates and an IPF-related guinea pig model, and the company is preparing for IND-enabling studies once financing is secured.
• The company is advancing Dipraglurant for post-stroke and traumatic brain injury recovery, citing preclinical evidence that mGlu5 inhibition may support neuroplasticity and improve sensorimotor recovery alongside rehabilitation.
• Addex ended Q1 2026 with CHF 0.9 million in cash and said a small Q2 capital raise, combined with low burn after the Neurosterix spin-out, gives it runway into Q4 2026.
• The company highlighted that its 20% stake in Neurosterix is not being fully reflected in Addex’s share price, while Neurosterix continues to advance its pipeline, including NTX-253 in Phase I with data expected in Q3.
• Q1 net loss was CHF 1.7 million, driven mainly by Addex’s share of Neurosterix losses, while operating loss improved slightly year over year due to lower outsourced R&D spending.

Addex Therapeutics Price Performance

ADXN stock opened at $6.07 on Friday. The firm has a market cap of $7.47 million, a price-to-earnings ratio of -1.06 and a beta of 1.48. Addex Therapeutics has a 1-year low of $5.41 and a 1-year high of $12.05. The firm has a fifty day moving average price of $6.66 and a two-hundred day moving average price of $7.12.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.